Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

  • STATUS
    Not Recruiting
  • participants needed
    45
  • sponsor
    Basilea Pharmaceutica
Updated on 18 June 2021
Investigator
Kamal Hamed, MD, MPH
Primary Contact
AZ Sint-Jan Brugge-Oostende AV (8.1 mi away) Contact
+16 other location
antibiotic therapy
antibiotics

Summary

The primary objective is to characterize the pharmacokinetics of single doses of ceftobiprole in neonates and infants aged 3 months. The secondary objective is to evaluate safety and tolerability of ceftobiprole in neonates and infants aged 3 months.

Details
Condition Bacterial Infection, Bacterial Infections
Treatment ceftobiprole
Clinical Study IdentifierNCT02527681
SponsorBasilea Pharmaceutica
Last Modified on18 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note